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. Mice were not irradiated or conditioned with busulfan prior to 1 3 9 transplantation to avoid perturbing leukemia niches. The mice were then euthanized and the CNS 1 4 0 examined by histopathology and immunohistochemistry. We identified both the meninges and, to a 1 4 1 lesser extent, the choroid plexus as the predominant CNS sites that harbor leukemia cells both before 1 4 2 and after treatment with systemic cytarabine (Supplemental Figure 1B) . In contrast, parenchymal 1 4 3 involvement by leukemia was a rare, and often late, finding. It is possible that the altered immune 1 4 4 system of NSG mice could influence CNS leukemia involvement or anatomic distribution. Accordingly, 1 4 5 we also tested a pre-B ALL mouse leukemia model that utilizes BCR/ABL p190 expression in 1 4 6 hematopoietic cells from Arf -/mice transplanted into immunocompetent mice 21, 22, 36 . Similar to the 1 4 7 xenotransplantation results, leukemia extensively involved the meninges in these mice (Supplemental 1 4 8 Figure 1C ). The meninges enhance leukemia chemoresistance. We then developed ex vivo co-culture 1 5 1 approaches to focus more specifically on the effects of the meninges on leukemia chemosensitivity. Meningeal cells shift the apoptotic balance toward survival in leukemia cells. In order to define 1 7 2 the mechanism of meningeal-mediated leukemia chemoresistance we next examined the effect of co- cytarabine or methotrexate treatment as determined by both caspase 3/7 activity and measurement of 9 the levels of several pro-apoptotic proteins (BID, caspase 3 & 8) decreased in leukemia cells co-1 8 0 cultured with meningeal cells ( Figure 2C ). However, assessing how the dynamic levels, activities, and 1 8 1 complex interactions of these and other BCL-2 family of pro-and anti-apoptotic proteins (BH3 proteins) 1 8 2 integrate to regulate the overall apoptotic balance is experimentally challenging. To try and capture 1 8 3 the overall effect of the meninges on leukemia apoptotic balance, we then utilized BH3 profiling, a 1 8 4 functional apoptosis assay that uses the response of mitochondria to perturbations by BH3 domain 1 8 5 peptides, such as BIM, to predict the degree to which cells are primed to undergo apoptosis by the 1 8 6 mitochondrial pathway 37,38 . Importantly, decreased mitochondrial priming following drug treatment has 1 8 7 been shown to be highly predictive of chemotherapy resistance in vitro and in vivo 37,38 . Accordingly, 1 8 8 we found that leukemia cells co-cultured with meningeal cells exhibited increased cytochrome C 1 8 9 retention upon exposure to the BIM peptide compared to leukemia cells in suspension ( Figure 2D ). These data suggest that leukemia cells co-cultured with meningeal cells are significantly less primed 1 9 1 to undergo apoptosis through the mitochondrial pathway than the same leukemia cells in suspension. Meningeal cells increase leukemia quiescence. We also examined the effect of the meninges on 1 9 4 leukemia cell cycle and quiescence. As shown in Figure 3A -C, leukemia cells co-cultured with primary 1 9 5 meningeal cells are less proliferative as shown by decreased Ki-67 staining, significantly decreased S 1 9 6 phase, and increased G0/G1 phase. We next used Hoechst-Pyronin Y staining to better distinguish 1 9 7 between G0 and G1 phases 29 . As shown in Figure 3D -F, leukemia cells in co-culture with primary 1 9 8 meningeal cells exhibited increased G0 phase, indicative of quiescence, relative to leukemia cells in 1 9 9 suspension. Glucose uptake also diminished in leukemia cells co-cultured with meningeal cells, 2 0 0 further supporting that these leukemia cells are quiescent (Supplemental Figure 4 ). We then examined cell cycle and quiescence in leukemia cells isolated from the meninges of 2 0 3 xenotransplanted mice. As shown in Figure 4A -C, leukemia cells isolated from the meninges of 2 0 4 transplanted mice exhibited increased G0/G1 phase and decreased Ki-67 staining relative to leukemia 2 0 5 cells isolated from peripheral blood or bone marrow. In order to assess whether the meninges harbor 2 0 6 long-term quiescent leukemia cells, we labeled leukemia cells with a fluorescent membrane dye (DiR 2 0 7 or DiD) that is retained in dormant, non-cycling cells but is diluted to undetectable levels within 3-5 2 0 8 generations in proliferating leukemia cells 28, [30] [31] [32] [33] . Dye-labeled leukemia cells were then transplanted 2 0 9 into immunodeficient mice. After systemic leukemia development in ~4 weeks, the mice were 2 1 0 euthanized and meninges harvested. Within the meninges we detected low levels of dye-retaining, 2 1 1 quiescent leukemia cells by flow cytometry (<1% of total leukemia population; Figure 4D -E). Further 2 1 2 supporting that these dye-retaining leukemia cells are quiescent, the dye-retaining leukemia cells from 2 1 3 the meninges exhibited low expression of the proliferation marker Ki-67 ( Figure 4F ). We also detected 2 1 4 these quiescent leukemia cells within the meninges using confocal microscopy ( Figure 4G -I). We next treated these xenotransplanted mice with cytarabine and measured the percentage of dye-2 1 6 retaining leukemia cells in the meninges by flow cytometry. Cytarabine was given at a dose previously 2 1 7
shown to result in plasma levels in the range of human high-dose cytarabine regimens that cross the 2 1 8 blood-brain barrier 27, 39 . Cytarabine, relative to PBS, also significantly reduced the CNS leukemia 2 1 9 burden in xenotransplanted mice and provides functional data that cytarabine is crossing the blood-2 2 0 brain barrier in our murine experiments. (Supplemental Figure 5 ). Moreover, the relative increase in 2 2 1 dye-retaining leukemia cells after cytarabine treatment is consistent with these cells having increased 2 2 2 chemoresistance compared to the dye-negative, proliferating leukemia cells ( Figure 4J ). Together 2 2 3 these data suggest the meninges harbor quiescent leukemia cells that exhibit chemoresistance. Meningeal-mediated leukemia chemoresistance is a reversible phenotype. We then tested 2 2 6 whether removal of leukemia cells from co-culture with meningeal cells restored chemosensitivity. Leukemia cells were dissociated from meningeal cells, purified with CD19 (NALM-6) or CD3 (Jurkat) 2 2 8 magnetic beads, and placed back in suspension. As shown in Figure 5A , leukemia cells removed from 2 2 9 co-culture exhibited similar sensitivity to methotrexate and cytarabine as leukemia cells in suspension. Similarly, leukemia cells grown in suspension after isolation from the meninges of xenotransplanted 2 3 1 mice also exhibited sensitivity to cytarabine ( Figure 5B ). Further supporting these results, leukemia 2 3 2 cells placed back into suspension after co-culture reverted back to baseline cell cycle and apoptosis 2 3 3 characteristics ( Figure 5C -E). These results suggest that drugs that disrupt adhesion between 2 3 4 leukemia and meningeal cells may restore leukemia chemosensitivity in the CNS niche. Overcoming meningeal-mediated leukemia chemoresistance by disrupting adhesion. Given 2 3 7 that meningeal-mediated leukemia chemoresistance is a reversible phenotype, we next identified 2 3 8 several cell adhesion inhibitors that disrupted leukemia-meningeal adhesion in co-culture 2 3 9 (Supplemental Figure 6A ). We selected Me6TREN for further testing based upon its effectiveness in 2 4 0 co-culture, small molecular weight (increasing likelihood for CNS penetration), tolerability in mice, lack 2 4 1 of prior testing in leukemia, and likely multifactorial mechanism of action 25,26 . As shown in Figure 6A , Figure 6B ). We then quantitated non-adherent leukemia cells in the control in order to measure disruption of leukemia adhesion in vivo. As shown in Figure 6B , Me6TREN treated mice showed a modest, but significant, increase in leukemia cells in the CSF, significantly attenuated leukemia chemoresistance in co-culture with meningeal cells ( Figure 6C ). We 2 5 0 next assessed the in vivo ability of Me6TREN to enhance the efficacy of cytarabine in treating 2 5 1 leukemia in the meninges. We tested NALM-6, Jurkat, and primary B-ALL leukemia cells with dosing Protection from leukemia relapse in the CNS is crucial to long-term survival and quality of life for 2 6 0 However, it is certainly possible, and perhaps even likely, that other cells or tissues within the CNS, We then used co-culture and in vivo xenotransplantation approaches to further characterize the 2 7 6 effects of the meninges on leukemia biology. We found that the meninges enhance leukemia 2 7 7 resistance to cytarabine and methotrexate, the primary drugs currently used in the treatment of CNS 2 7 8 leukemia, by altering the apoptotic balance in leukemia cells to favor survival and increasing leukemia 2 7 9 quiescence 1,2 . Quiescence allows cancer cells to escape cytotoxic chemotherapy and has been 2 8 0 shown to be critical for leukemia relapse and stem cell biology 28, 51, 52 . In agreement, it was previously 2 8 1
shown that high Mer kinase expressing, t(1;19) leukemia cells co-cultured with CNS-derived cells To define the mechanism by which the meninges exert these effects on leukemia biology, we also xenotransplanted mice reverted back to baseline cell cycle, quiescence, apoptosis balance, and relapse-inducing ALL cells within the bone marrow that exhibited dormancy, stemness, and treatment 3 0 2 resistance 30 . However, similar to our results, these therapeutically adverse properties were reversed 3 0 3 when these leukemia cells were dissociated from the bone marrow microenvironment. We then identified drugs capable of disrupting leukemia-meningeal adhesion. In addition to identifying 3 0 6 several drugs that inhibit canonical cell adhesion targets, we also found that Me6TREN, a novel biologic agents, that target leukemia-niche interactions may exhibit broader specificity than mutation-3 1 2 specific therapeutics that are limited by the genetic heterogeneity of leukemia. The mechanism by 3 1 3 which Me6TREN disrupts the leukemia niche is not known. However, Me6TREN mobilizes mouse 3 1 4 hematopoietic stem/progenitor cells from the bone marrow through effects on several cell adhesion 3 1 5 and migration pathways including MMP-9, SDF-1/CXCR4, and VECAM/VLA-4 25 . As these adhesion 3 1 6 pathways also contribute to the bone marrow leukemia niche, it is possible that Me6TREN may exhibit for use in upfront therapy to reduce the risk for CNS relapse. Given the complexity of cell-cell interactions, this multi-faceted mechanism of action of Me6TREN 3 2 2 may provide an advantage relative to other niche-disrupting agents being developed for leukemia 3 2 3 therapy that target a single mechanism of retention or adhesion (i.e. inhibitors of SDF-1 or a single 3 2 4 extracellular adhesion factor) 56 . An alternative approach to overcome the complexity and redundancy 3 2 5 of cellular adhesion would be to combine multiple inhibitors that target different adhesion molecules 3 2 6 (Supplemental Figure 6A ). A potential risk of combining Me6TREN, or other niche-disrupting agents, and chemotherapy is that normal HSCs mobilized into the circulation by ME6TREN may be sensitized to chemotherapy with 3 3 0 resulting marrow aplasia or delayed hematopoietic recovery. However, we found that mice receiving The authors declare no competing financial interests. long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis. t-test. SEM from three independent experiments and P: ****, <0.0001 by ANOVA. ns, not significant. cytarabine 500 nM and after 48 hours viability assessed with annexin-V staining and flow cytometry. 
